Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Related Keywords

Copenhagen ,Køavn ,Denmark ,Ukraine ,Russia ,Franziska Burianek ,Edna Kaplan ,Daniel Vitt ,Paula Schwartz ,Jessica Breu ,Exchange Commission ,Rx Communications Group ,Immunic Inc ,Nasdaq ,United European Gastroenterology Week ,Chief Executive Officer ,Human Trial ,Barrier Regeneration ,Senior Medical Director ,Moderated Posters ,Poster Stage ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,Immunic ,Nc ,